<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">tumors</journal-id><journal-title-group><journal-title xml:lang="ru">Malignant tumours</journal-title><trans-title-group xml:lang="en"><trans-title>Malignant tumours</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2224-5057</issn><issn pub-type="epub">2587-6813</issn><publisher><publisher-name>Rosoncoweb</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18027/2224-5057-2023-13-2-8</article-id><article-id custom-type="elpub" pub-id-type="custom">tumors-1103</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЕ СЛУЧАИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL NOTES</subject></subj-group></article-categories><title-group><article-title>Иммуноопосредованная саркоидозо-подобная реакция на фоне терапии ингибиторами контрольных точек</article-title><trans-title-group xml:lang="en"><trans-title>Checkpoint inhibitor-induced immune-related sarcoidosis-like reaction</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шакиров</surname><given-names>Р. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Shakirov</surname><given-names>R. R.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Шакиров Ренат Р. - врач-онколог отделения онкологии № 1.</p><p>Москва</p></bio><bio xml:lang="en"><p>Renat R. Shakirov - oncologist, Oncology Department No. 1, Moscow Treatment and Rehabilitation Center.</p><p>Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Базин</surname><given-names>И. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Basin</surname><given-names>I. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Базин Игорь С. – доктор медицинских наук, ведущий научный сотрудник, химиотерапевтическое отделение № 2, ФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава России.</p><p>Москва</p></bio><bio xml:lang="en"><p>Igor S. Basin - MD, PhD, DSc, Senior Research Scientist, Chemotherapy Department, No. 2, N.N. Blokhin National Medical Research Center of Oncology.</p><p>Moscow</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Крашихина</surname><given-names>Т. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Krashikhina</surname><given-names>T. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Крашихина Татьяна В. - заведующая отделением онкологии № 1.</p><p>Москва</p></bio><bio xml:lang="en"><p>Tatiana V. Krashikhina - Head of the Oncology Department No. 1, Moscow Treatment and Rehabilitation Center.</p><p>Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Текеева</surname><given-names>А. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Tekeeva</surname><given-names>A. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Текеева Асият И. - врач-онколог отделения онкологии № 1.</p><p>Москва</p></bio><bio xml:lang="en"><p>Asiiat I. Tekeeva - oncologist, Oncology Department No. 1, Moscow Treatment and Rehabilitation Center.</p><p>Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Чернышева</surname><given-names>Е. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Chernysheva</surname><given-names>E. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Чернышева Екатерина С.- кандидат медицинских наук, заместитель главного врача по медицинской части.</p><p>Москва</p></bio><bio xml:lang="en"><p>Ekaterina S. Chernysheva - MD, PhD, Deputy Physician-in-Chief for Medicine, Moscow Treatment and Rehabilitation Center.</p><p>Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лядов</surname><given-names>К. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Lyadov</surname><given-names>K. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Лядов Константин В. - академик РАН, доктор медицинских наук, профессор, главный врач.</p><p>Москва</p></bio><bio xml:lang="en"><p>Konstantin V. Lyadov - MD, PhD, DSc, Professor, Academician of the Russian Academy of Sciences, Physician-in-Chief, Moscow Treatment and Rehabilitation Center.</p><p>Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Общество с ограниченной ответственностью «Московский центр восстановительного лечения»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Moscow Treatment and Rehabilitation Center</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Общество с ограниченной ответственностью «Московский центр восстановительного лечения»; ФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Moscow Treatment and Rehabilitation Center; N.N. Blokhin National Medical Research Center of Oncology</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>14</day><month>03</month><year>2023</year></pub-date><volume>13</volume><issue>2</issue><fpage>107</fpage><lpage>112</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Шакиров Р.Р., Базин И.С., Крашихина Т.В., Текеева А.И., Чернышева Е.С., Лядов К.В., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Шакиров Р.Р., Базин И.С., Крашихина Т.В., Текеева А.И., Чернышева Е.С., Лядов К.В.</copyright-holder><copyright-holder xml:lang="en">Shakirov R.R., Basin I.S., Krashikhina T.V., Tekeeva A.I., Chernysheva E.S., Lyadov K.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.malignanttumors.org/jour/article/view/1103">https://www.malignanttumors.org/jour/article/view/1103</self-uri><abstract><p>Применение терапии ингибиторами контрольных точек может сопровождаться развитием иммуноопосредованных осложнений самого различного спектра и степени тяжести. Одним из достаточно редких, но важных по клинической сути, являются иммуноопосредованные саркоидозо-подобные реакции. Данные изменения, за счет рентгенографического появления активных измененных лимфатических узлов или узелков в иных органах, могут быть ложно трактованы как прогрессирование или стабилизация основного онкологического заболевания и, таким образом, повлиять на тактику лечения, приводя к необоснованно ранней отмене терапии или её ненужному продолжению. Ввиду отсутствия на настоящий момент убедительных критериев отличия саркоидозо-подобной реакции и саркоидоза, необходима осведомленность онкологов о возможности подобной реакции для включения ее в дифференциальный диагноз при подозрениях на прогрессирование у пациентов, получающих иммунотерапию ингибиторами контрольных точек.</p></abstract><trans-abstract xml:lang="en"><p>Immune checkpoint inhibitors are associated with a wide spectrum of immune-related adverse events (AE) of different severity. Immune-related sarcoidosis-like reactions are relatively rare but clinically important AEs. These abnormalities, due to the appearance of active pathological lymph nodes or nodules in other organs on radiographs, can be falsely interpreted as tumor progression or stabilization and thus affect treatment strategy, leading to unreasonably early therapy discontinuation or its unnecessary continuation. So far there were no convincing criteria for differentiation between sarcoidosis-like reaction and sarcoidosis, oncologist should be aware of this reaction and include it in the differential diagnosis in patient with suspected disease progression who are treated with immune checkpoint inhibitors.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>иммунотерапия</kwd><kwd>нежелательные лекарственные реакции</kwd><kwd>саркоидоз</kwd><kwd>ингибиторы контрольных точек</kwd></kwd-group><kwd-group xml:lang="en"><kwd>immunotherapy</kwd><kwd>adverse drug reactions</kwd><kwd>sarcoidosis</kwd><kwd>checkpoint inhibitors</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Martins F., Sofiya L., Sykiotis G. P., Lamine F., Maillard M., Fraga M., Shabafrouz K. et al. Adverse effects of immune-checkpoint inhibitors : epidemiology, management and surveillance // Nat. Rev. Clin. Oncol, 2019, том 16 № 9, стр. 563-580.</mixed-citation><mixed-citation xml:lang="en">Martins F., Sofiya L., Sykiotis G. P., Lamine F., Maillard M., Fraga M., Shabafrouz K. et al. Adverse effects of immune-checkpoint inhibitors : epidemiology, management and surveillance // Nat. Rev. Clin. Oncol, 2019,16 № 9, p. 563–580.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Wang D.Y., Salem J .- E., Cohen J.V., Chandra S., Menzer C., Ye F. et al. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors : A Systematic Review and Meta-analysis // JAMA Oncol, 2018, том 4, № 12. стр. 1721-1728. Chopra A., Nautiyal A., Kalkanis A., Judson M. A. Drug-Induced Sarcoidosis-Like Reactions // Chest, 2018, том Sep 154 (3), стр. 664-677.</mixed-citation><mixed-citation xml:lang="en">Wang D. Y., Salem J .– E., Cohen J. V., Chandra S., Menzer C., Ye F. et al. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors : A Systematic Review and Meta-analysis // JAMA Oncol, 2018,4, № 12. p. 1721–1728.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">El Jammal T., Pavic M., Gerfaud-Valentin M., Jamilloux Y., Seve P. Sarcoidosis and Cancer : A Complex Relationship// Front. Med., 2020, том 7, статья 594118.</mixed-citation><mixed-citation xml:lang="en">Chopra A., Nautiyal A., Kalkanis A., Judson M. A. Drug-Induced Sarcoidosis-Like Reactions // Chest, 2018, Sep 154 (3), p. 664–677.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Jespersen H., Bjursten S., Ny L., Levin M. Checkpoint inhibitor-induced sarcoid reaction mimicking bone metastases// Lancet Oncol., 2018, том 19 (6) : e327.</mixed-citation><mixed-citation xml:lang="en">El Jammal T., Pavic M., Gerfaud-Valentin M., Jamilloux Y., Sève P. Sarcoidosis and Cancer : A Complex Relationship // Front. Med., 2020,7, article 594118.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Purohit B. S., Ailianou A., Dulguerov N., Becker C.D., Ratib O., Becker M. FDG-PET / CT pitfalls in oncological head and neck imaging// Insights Imaging, 2014, том 5, стр. 585-602.</mixed-citation><mixed-citation xml:lang="en">Jespersen H., Bjursten S., Ny L., Levin M. Checkpoint inhibitor-induced sarcoid reaction mimicking bone metastases // Lancet Oncol., 2018, 19 (6) : e327.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Takamochi K., Yoshida J., Murakami K., Niho S., Ishii G., Nishimura M. et al. Pitfalls in lymph node staging with positron emission tomography in non-small cell lung cancer patients // Lung Cancer, 2004, том 47 (2), стр. 235-242. Kruger S., Buck A.K., Mottaghy F.M., Pauls S., Schelzig H., Hombach V. et al. Use of integrated FDG-PET / CT in sarcoidosis// Clin. Imaging, 2008, том 32 (4), стр. 269-273.</mixed-citation><mixed-citation xml:lang="en">Purohit B. S., Ailianou A., Dulguerov N., Becker C. D., Ratib O., Becker M. FDG-PET / CT pitfalls in oncological head and neck imaging // Insights Imaging, 2014, 5, p. 585–602.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Ammar A., Zahia E., Bali, Daniel S. et al. Sarcoidosis-Like Granulomatous Lymphadenopathy Mistaken for Neoplastic Disease on Positron Emission Tomography// J. Investig. Med. High Impact Case Rep., 2019, том 7, стр. 1-3.</mixed-citation><mixed-citation xml:lang="en">Takamochi K., Yoshida J., Murakami K., Niho S., Ishii G., Nishimura M. et al. Pitfalls in lymph node staging with positron emission tomography in non-small cell lung cancer patients // Lung Cancer, 2004, 47 (2), p. 235–242.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Krüger S., Buck A. K., Mottaghy F. M., Pauls S., Schelzig H., Hombach V. et al. Use of integrated FDG-PET / CT in sarcoidosis // Clin. Imaging, 2008, 32 (4), p. 269–273.</mixed-citation><mixed-citation xml:lang="en">Krüger S., Buck A. K., Mottaghy F. M., Pauls S., Schelzig H., Hombach V. et al. Use of integrated FDG-PET / CT in sarcoidosis // Clin. Imaging, 2008, 32 (4), p. 269–273.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Ammar A., Zahia E., Bali, Daniel S. et al. Sarcoidosis-Like Granulomatous Lymphadenopathy Mistaken for Neoplastic Disease on Positron Emission Tomography // J. Investig. Med. High Impact Case Rep., 2019, 7, p. 1–3.</mixed-citation><mixed-citation xml:lang="en">Ammar A., Zahia E., Bali, Daniel S. et al. Sarcoidosis-Like Granulomatous Lymphadenopathy Mistaken for Neoplastic Disease on Positron Emission Tomography // J. Investig. Med. High Impact Case Rep., 2019, 7, p. 1–3.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru"></mixed-citation><mixed-citation xml:lang="en"></mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
